This article shines a light on the treatment of venous thromboembolism (VTE), a condition with higher rates of morbidity and mortality than both breast and prostate cancer. David Sutton, Co-director at Staffordshire Thrombosis and Anticoagulation Centre, University Hospitals North Midlands, UK, and Sue Rhodes, VTE Clinical Nurse Specialist and Joint Anticoagulant Lead, Great Western Hospitals, Swindon, UK, share their leading insights in an area with evolving treatment options.
Allergy & Immunology
